These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1389 related articles for article (PubMed ID: 9551360)
1. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines. Fenton RG; Turcovski-Corrales SM; Taub DD J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360 [TBL] [Abstract][Full Text] [Related]
2. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519 [TBL] [Abstract][Full Text] [Related]
3. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853 [TBL] [Abstract][Full Text] [Related]
4. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004 [TBL] [Abstract][Full Text] [Related]
5. CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes. de Waal Malefyt R; Verma S; Bejarano MT; Ranes-Goldberg M; Hill M; Spits H Eur J Immunol; 1993 Feb; 23(2):418-24. PubMed ID: 7679643 [TBL] [Abstract][Full Text] [Related]
6. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882 [TBL] [Abstract][Full Text] [Related]
7. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes. Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164 [TBL] [Abstract][Full Text] [Related]
8. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells. Yang S; Darrow TL; Seigler HF Cancer Res; 1997 Apr; 57(8):1561-8. PubMed ID: 9108460 [TBL] [Abstract][Full Text] [Related]
9. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334 [TBL] [Abstract][Full Text] [Related]
11. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396 [TBL] [Abstract][Full Text] [Related]
12. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Zajac P; Schütz A; Oertli D; Noppen C; Schaefer C; Heberer M; Spagnoli GC; Marti WR Cancer Res; 1998 Oct; 58(20):4567-71. PubMed ID: 9788602 [TBL] [Abstract][Full Text] [Related]
13. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300 [TBL] [Abstract][Full Text] [Related]
14. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro. Imro MA; Dellabona P; Manici S; Heltai S; Consogno G; Bellone M; Rugarli C; Protti MP Hum Gene Ther; 1998 Jun; 9(9):1335-44. PubMed ID: 9650618 [TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898 [TBL] [Abstract][Full Text] [Related]
16. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Sulé-Suso J; Arienti F; Melani C; Colombo MP; Parmiani G Eur J Immunol; 1995 Oct; 25(10):2737-42. PubMed ID: 7589065 [TBL] [Abstract][Full Text] [Related]
17. Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells. Mackensen A; Wittnebel S; Veelken H; Noppen C; Spagnoli GC; Lindermann A Eur Cytokine Netw; 1999 Sep; 10(3):329-36. PubMed ID: 10477389 [TBL] [Abstract][Full Text] [Related]
18. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. Li Y; McGowan P; Hellström I; Hellström KE; Chen L J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929 [TBL] [Abstract][Full Text] [Related]
19. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. Lanier LL; O'Fallon S; Somoza C; Phillips JH; Linsley PS; Okumura K; Ito D; Azuma M J Immunol; 1995 Jan; 154(1):97-105. PubMed ID: 7527824 [TBL] [Abstract][Full Text] [Related]
20. Antigen presentation by interferon-gamma-treated thyroid follicular cells inhibits interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells. Lombardi G; Arnold K; Uren J; Marelli-Berg F; Hargreaves R; Imami N; Weetman A; Lechler R Eur J Immunol; 1997 Jan; 27(1):62-71. PubMed ID: 9021999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]